应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
02162 康诺亚-B
已收盘 09-29 16:08:04
79.600
+6.450
+8.82%
最高
81.200
最低
75.000
成交量
426.03万
今开
75.000
昨收
73.150
日振幅
8.48%
总市值
238.00亿
流通市值
238.00亿
总股本
2.99亿
成交额
3.37亿
换手率
1.42%
流通股本
2.99亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
康诺亚-B午后涨逾9% 公司在自免、肿瘤等多个创新药领域具备强竞争优势
新浪港股 · 13:44
康诺亚-B午后涨逾9% 公司在自免、肿瘤等多个创新药领域具备强竞争优势
创新药概念股逆市走强 康方生物（09926）涨16.85%、康诺亚-B（02162）涨10.32%
金吾财讯 · 13:20
创新药概念股逆市走强 康方生物（09926）涨16.85%、康诺亚-B（02162）涨10.32%
港股异动 | 康诺亚-B(02162.HK)盘中涨超8% 公司在自免、肿瘤等多个创新药领域具备强竞争优势
智通财经 · 11:06
港股异动 | 康诺亚-B(02162.HK)盘中涨超8% 公司在自免、肿瘤等多个创新药领域具备强竞争优势
异动解读｜康诺亚-B盘中上涨8.48%，创新药板块受依沃西OS数据及阿斯利康战略投资提振
行情直击 · 10:27
异动解读｜康诺亚-B盘中上涨8.48%，创新药板块受依沃西OS数据及阿斯利康战略投资提振
生物医药板块全线走低 诺诚健华（09969）跌10.48% 机构指行业需求尚未明显回暖
金吾财讯 · 09-24
生物医药板块全线走低 诺诚健华（09969）跌10.48% 机构指行业需求尚未明显回暖
康诺亚-B 2026年上半年营收6.17亿元，经调整净利润12.18亿元
公告速递 · 09-22
康诺亚-B 2026年上半年营收6.17亿元，经调整净利润12.18亿元
港股异动 | 创新药概念股全线爆发 据报美国拟放宽药企授权许可合作 创新药BD估值有望修复
智通财经 · 09-21
港股异动 | 创新药概念股全线爆发 据报美国拟放宽药企授权许可合作 创新药BD估值有望修复
创新药概念股早盘全线爆发 康诺亚-B及康方生物均涨逾9%
新浪港股 · 09-21
创新药概念股早盘全线爆发 康诺亚-B及康方生物均涨逾9%
港股生物医药股全线大涨，金斯瑞涨超6%，药明康德涨超3%
老虎快讯 · 09-21
港股生物医药股全线大涨，金斯瑞涨超6%，药明康德涨超3%
生物医药板块盘初普升 复宏汉霖（02696）涨7.96% 机构指中国创新药进入全球价值兑现阶段
金吾财讯 · 09-21
生物医药板块盘初普升 复宏汉霖（02696）涨7.96% 机构指中国创新药进入全球价值兑现阶段
异动解读｜康诺亚-B盘中上涨5.41%，国际化授权持续落地叠加行业板块走强
行情直击 · 09-21
异动解读｜康诺亚-B盘中上涨5.41%，国际化授权持续落地叠加行业板块走强
康诺亚-B(02162)：王闽川辞任非执行董事
智通财经 · 09-06
康诺亚-B(02162)：王闽川辞任非执行董事
康诺亚-B(02162.HK)：王闽川辞任非执行董事
智通财经 · 09-06
康诺亚-B(02162.HK)：王闽川辞任非执行董事
康诺亚-B（02162）公布董事会及三大专门委员会组成人员名单
公告速递 · 09-06
康诺亚-B（02162）公布董事会及三大专门委员会组成人员名单
康诺亚-B（02162.HK）：王闽川博士将于2026年9月4日辞任非执行董事
公告速递 · 09-06
康诺亚-B（02162.HK）：王闽川博士将于2026年9月4日辞任非执行董事
【券商聚焦】交银国际：医药行业收入稳健增长 多重利好推动盈利表现显著改善
金吾财讯 · 09-04
【券商聚焦】交银国际：医药行业收入稳健增长 多重利好推动盈利表现显著改善
港股异动 | 康诺亚-B(02162.HK)涨超3% 公司国际化战略迎重要里程碑 与Aeira签署独家许可协议
智通财经 · 09-03
港股异动 | 康诺亚-B(02162.HK)涨超3% 公司国际化战略迎重要里程碑 与Aeira签署独家许可协议
康诺亚-B与Aeira签订司普奇拜单抗东南亚及中亚18国独家许可协议
公告速递 · 09-02
康诺亚-B与Aeira签订司普奇拜单抗东南亚及中亚18国独家许可协议
东方证券股份有限公司(DFZQ)减持康诺亚-B(02162.HK)4.8万股 每股作价78.401港元
智通财经 · 09-02
东方证券股份有限公司(DFZQ)减持康诺亚-B(02162.HK)4.8万股 每股作价78.401港元
康诺亚-B公布2026年8月股份变动月报表，股本保持稳定
公告速递 · 09-02
康诺亚-B公布2026年8月股份变动月报表，股本保持稳定
加载更多
公司概况
公司名称：
康诺亚-B
所属市场：
SEHK
上市日期：
--
主营业务：
康诺亚生物医药科技有限公司是一家生物科技公司，专注于自主发现及开发自体免疫及肿瘤治疗领域的创新生物疗法的公司。该公司还专注于医药产品的研究和开发。该公司的主要产品有CM310、CM326、CM313和CM383，可治疗各种成人、青少年及儿童I型免疫性疾病，例如中重度特应性皮炎、中重度哮喘、慢性鼻賨炎伴鼻息肉、过敏性鼻炎，亦可能可以治疗慢性阻塞性肺疾病。该公司还建立了涵盖生物药开发的关键功能的全面一体化平台。该公司主要在中国国内和海外市场开展业务。
发行价格：
--
{"stockData":{"symbol":"02162","market":"HK","secType":"STK","nameCN":"康诺亚-B","latestPrice":79.6,"timestamp":1790669284003,"preClose":73.15,"halted":0,"volume":4260252,"delay":0,"changeRate":0.08817498291182485,"floatShares":299000000,"shares":299000000,"eps":-1.91,"marketStatus":"已收盘","change":6.45,"latestTime":"09-29 16:08:04","open":75,"high":81.2,"low":75,"amount":336587517,"amplitude":0.084757,"askPrice":79.65,"askSize":6000,"bidPrice":79.55,"bidSize":3500,"shortable":3,"etf":0,"ttmEps":3.044545,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790731800000},"marketStatusCode":5,"adr":0,"listingDate":1625673600000,"exchange":"SEHK","adjPreClose":73.15,"openAndCloseTimeList":[[1790645400000,1790654400000],[1790658000000,1790668800000]],"volumeRatio":3.309863,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02162","defaultTab":"news","newsList":[{"id":"2671451293","title":"康诺亚-B午后涨逾9% 公司在自免、肿瘤等多个创新药领域具备强竞争优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2671451293","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671451293?lang=zh_cn&edition=full","pubTime":"2026-09-29 13:44","pubTimestamp":1790660640,"startTime":"0","endTime":"0","summary":"模拟交易客户端康诺亚-B午后涨超8%，截至发稿，股价上涨8.95%，现报79.70港元，成交额2.37亿港元。本月初，康诺亚宣布已与跨国医药公司 Aeira 就司普奇拜单抗注射液在东南亚和中亚等 18 个国家和地区的上市注册和商业化达成许可协议。中邮证券指出，康诺亚作为国内创新药出海新锐，在自免、肿瘤等多个创新药领域具备强竞争优势。2023年2月，阿斯利康以6300万美元首付款、超过11亿美元的里程碑付款拿下它的全球权益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-29/doc-initnmwi2954177.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","BK1583","LNGR","MEDX","IBBQ","159992","02162","BK1161","BK1587","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671293354","title":"创新药概念股逆市走强 康方生物（09926）涨16.85%、康诺亚-B（02162）涨10.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671293354","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671293354?lang=zh_cn&edition=full","pubTime":"2026-09-29 13:20","pubTimestamp":1790659249,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念股逆市走强，康方生物 涨16.85%，康诺亚-B涨10.32%，乐普生物涨7.88%，荣昌生物涨5.41%，科伦博泰生物涨5.32%，博安生物涨4.74%，恒瑞医药涨4.02%，再鼎医药涨4.02%。根据Insight数据，除已经在美国获批上市的药物外，已达成出海合作的国产创新药中有27款处于临床后期。其中，依沃西单抗、匹米替尼已在美国申请上市，芦康沙妥珠单抗、伦康依隆妥单抗、SSGJ-707等重点品种处于临床III期。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992749","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU1023057109.AUD","BK1587","BK1191","IE00BPRC5H50.USD","LU2476274308.USD","IBBQ","06955","LU0348827113.USD","LU0417516902.SGD","LU1961090484.USD","LU2488822045.USD","02162","MEDX","KURE","09926","LU1720050803.USD","159992","LU0417516738.SGD","BK1583","LU0561508036.HKD","06978","LU2543165471.USD","02157","BK1588","LU1969619763.USD","LU2476274720.SGD","09995","LU0359201885.HKD","LU0196878994.USD","LU2328871848.SGD","LU0348766576.USD","LU2778985437.USD","LU0348735423.USD","LU0348767384.USD","BK1574","LU0359201612.USD","LU0417516571.SGD","IE00B5MMRT66.SGD","09688","LNGR","LU0348784397.USD","LU0359202008.SGD","LU1794554557.SGD","01276","06990","LU0348825331.USD","LU0634319403.HKD","IE00B543WZ88.USD","LU0348783233.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671267526","title":"港股异动 | 康诺亚-B(02162.HK)盘中涨超8% 公司在自免、肿瘤等多个创新药领域具备强竞争优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2671267526","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671267526?lang=zh_cn&edition=full","pubTime":"2026-09-29 11:06","pubTimestamp":1790651193,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1587","BK1161","BK1574","02162","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183161849","title":"异动解读｜康诺亚-B盘中上涨8.48%，创新药板块受依沃西OS数据及阿斯利康战略投资提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1183161849","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183161849?lang=zh_cn&edition=full","pubTime":"2026-09-29 10:27","pubTimestamp":1790648834,"startTime":"0","endTime":"0","summary":"9月29日，康诺亚-B盘中上涨8.48%，报79.35港元，成交额1.25亿港元。康方生物盘中涨超11%，板块情绪共振带动康诺亚-B等自免及肿瘤管线标的跟涨。机构指出，创新药板块正迎来临床数据兑现与海外BD授权落地的估值修复窗口。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康诺亚-B异动拉升，创新药双重利好引爆","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669451177","title":"生物医药板块全线走低 诺诚健华（09969）跌10.48% 机构指行业需求尚未明显回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2669451177","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669451177?lang=zh_cn&edition=full","pubTime":"2026-09-24 13:36","pubTimestamp":1790228201,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股生物医药板块午后全线走低，截至发稿，诺诚健华 跌10.48%，荣昌生物跌7.99%，复宏汉霖跌7.68%，康诺亚-B跌5.86%，再鼎医药跌5.32%，君实生物跌4.53%，金斯瑞生物科技跌4.21%，康方生物跌3.54%，科伦博泰生物跌3.11%，泰格医药跌2.35%，药明生物跌1.80%，百济神州跌1.56%，药明合联跌1.12%。消息面上，国盛证券发布研报称，医药行业需求尚未明显回暖，降本增效、费用精细化管理已成为利润端的重要支撑。下半年关注流感旺季带来的阶段性需求催化。","market":"other","thumbnail":"https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992441","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548","LU0828237510.HKD","LU0348825331.USD","161726","09995","LU1961090484.USD","BK1141","09926","02696","02268","09688","399441","BK1576","688428","KURE","LU0856984785.SGD","LU2328871848.SGD","LU3063872942.SGD","SG9999002562.SGD","LU0516422366.SGD","LU0561508036.HKD","BK4581","LU2039709279.SGD","LU0348783233.USD","LU2399975544.HKD","LU1242518931.SGD","SG9999014674.SGD","01877","02269","LU0456846285.SGD","03347","LU1242518857.USD","XBI","LU0540923850.HKD","BK1515","HK0000306701.USD","02162","LU1770034418.SGD","06160","09969","LU1303224171.USD","LU1719994722.HKD","BK1583","LU0516423174.USD","LU0140636845.USD","LU0348766576.USD","LU1880383366.USD","SG9999002463.SGD","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107414156","title":"康诺亚-B 2026年上半年营收6.17亿元，经调整净利润12.18亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1107414156","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107414156?lang=zh_cn&edition=full","pubTime":"2026-09-22 17:09","pubTimestamp":1790068191,"startTime":"0","endTime":"0","summary":"康诺亚-B在2026年上半年实现营收6.17亿元，同比上涨24%。期内经调整净利润为12.18亿元，上一年同期则为亏损0.79亿元。毛利从上年同期的4.65亿元增加至4.98亿元。报告期内，经营活动所用净现金流量为2.54亿元，较上年同期多支出0.73亿元。报告期内，“康悦达”在医院准入和城市覆盖方面取得较好进展，实现销售收入3.93亿元，同比增长132%，在公司整体收入增长中贡献明显。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康诺亚-B 2026年上半年营收6.17亿元，经调整净利润12.18亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669139135","title":"港股异动 | 创新药概念股全线爆发 据报美国拟放宽药企授权许可合作 创新药BD估值有望修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2669139135","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669139135?lang=zh_cn&edition=full","pubTime":"2026-09-21 13:43","pubTimestamp":1789969421,"startTime":"0","endTime":"0","summary":"意味着新规不会一刀切封禁全部生物医药跨境交易，肿瘤ADC、双抗等常规抗癌创新药，允许海外药企收购管线、开展授权BD合作。中信建投指出，2026年世界肺癌大会中，中国创新药在肺癌领域全面发力，多个项目从早期探索迈入III期临床与全球化阶段。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498535.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2778985437.USD","LU0634319403.HKD","BK4585","LU2476274308.USD","LU1720050803.USD","LNGR","LU0326950275.SGD","LU2097828474.EUR","BK1587","BK4588","HK0000165453.HKD","LU1961090484.USD","IE00B5MMRT66.SGD","159992","09926","LU0348735423.USD","BK1589","LU0417516571.SGD","KURE","LU0149534421.HKD","06978","LU2476274720.SGD","01801","LU0561508036.HKD","LU2097828631.EUR","LU1831875114.USD","LU0455707207.USD","LU0348784397.USD","BK1161","LU2399975544.HKD","LU0502904849.HKD","LU2242644610.SGD","MEDX","LU0244354667.USD","LU1794554557.SGD","LU1969619763.USD","IE00B543WZ88.USD","BK1574","LU2488822045.USD","02162","09969","LU0348767384.USD","VXUS","BK1583","LU2097828714.EUR","LU0348766576.USD","KCAI","LU0417516738.SGD","IBBQ","IE00BPRC5H50.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2669134373","title":"创新药概念股早盘全线爆发 康诺亚-B及康方生物均涨逾9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669134373","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669134373?lang=zh_cn&edition=full","pubTime":"2026-09-21 11:31","pubTimestamp":1789961460,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端创新药概念股早盘全线爆发，截至发稿，康诺亚-B（02162）上涨9.09%，报78.60港元；康方生物（09926）上涨8.90%，报98.55港元；诺诚健华（09969）上涨5.91%，报15.58港元；信达生物（01801）上涨6.21%，报102.60港元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-21/doc-inisqeue5914872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2778985437.USD","LU2488822045.USD","LU2476274308.USD","09926","LU0417516902.SGD","LU0348825331.USD","MEDX","LU0348766576.USD","LU2399975544.HKD","LU0417516738.SGD","06978","LU0561508036.HKD","LU0348827113.USD","LU0634319403.HKD","LU0348735423.USD","LNGR","LU1961090484.USD","02162","BK1161","KURE","LU0540923850.HKD","IE00B543WZ88.USD","LU0348783233.USD","LU0417516571.SGD","IBBQ","LU1794554557.SGD","BK1583","BK1587","159992","LU0348767384.USD","LU0348784397.USD","IE00BPRC5H50.USD","LU1720050803.USD","LU2476274720.SGD","BK1574","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153938851","title":"港股生物医药股全线大涨，金斯瑞涨超6%，药明康德涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1153938851","media":"老虎快讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153938851?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:14","pubTimestamp":1789956879,"startTime":"0","endTime":"0","summary":"港股市场生物医药股全线大涨，其中，复宏汉霖涨超10%，君实生物、康方生物涨超8%，康诺亚-B、诺诚健华涨超7%，荣昌生物、金斯瑞生物科技、药明生物、科伦博泰生物涨超6%，药明康德、泰格医药、药明合联涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03347","02269","01548","02696","01877","09926","02268","06990","02359","09995","02162","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669136031","title":"生物医药板块盘初普升 复宏汉霖（02696）涨7.96% 机构指中国创新药进入全球价值兑现阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2669136031","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669136031?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:49","pubTimestamp":1789955355,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股生物医药板块盘初普升，截至发稿，复宏汉霖 涨7.96%，诺诚健华涨7.34%，荣昌生物涨6.69%，康诺亚-B涨6.52%，康方生物涨6.46%，君实生物涨6.41%，金斯瑞生物科技涨5.80%，科伦博泰生物涨5.63%，药明生物涨4.47%，药明康德涨2.90%，泰格医药涨2.69%，百济神州涨2.07%，药明合联涨1.75%。中信证券表示，中国创新药进入全球价值兑现阶段，头部国际化创新药企业有望迎来产品全球价值兑现期。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992049","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","BK1610","LU0320764243.SGD","BK1588","LU0244354667.USD","LU0463099449.HKD","LU0029874905.USD","LU2476274720.SGD","BK4588","03347","LU0052750758.USD","BK1515","LU1188198961.HKD","09995","LU0326950275.SGD","LU0348784397.USD","399441","LU0540923850.HKD","LU0561508036.HKD","LU0979878070.USD","XBI","HK0000165453.HKD","LU1303224171.USD","01877","02696","02162","LU2488822045.USD","02268","LU0456827905.SGD","LU1961090484.USD","KURE","LU0320764599.SGD","LU0327786744.USD","LU0516422952.EUR","LU0348767384.USD","LU0196878994.USD","LU0348766576.USD","01548","LU1880383366.USD","06160","02359","02269","09926","161726","LU2242644610.SGD","LU0634319403.HKD","LU2045819591.USD","09969","LU0128522744.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147290751","title":"异动解读｜康诺亚-B盘中上涨5.41%，国际化授权持续落地叠加行业板块走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1147290751","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147290751?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:41","pubTimestamp":1789954876,"startTime":"0","endTime":"0","summary":"9月21日，康诺亚-B盘中上涨5.41%，报75.95港元，成交额3134.12万港元。消息面上，公司近期与跨国医药公司Aeira签署独家许可协议，将自主研发的靶向IL-4Rα单抗司普奇拜单抗注射液在东南亚、中亚及港澳地区共18个国家和地区的上市注册与商业化权益授出，标志着公司国际化战略迎来重要里程碑。此外，公司上半年实现营收6.17亿元人民币，净利润12.18亿元，同比扭亏；核心管线CM512获突破性治疗认定且II期临床达到全部终点，CMG901全球III期试验取得积极顶线结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康诺亚-B国际化授权落地，股价强势上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665646113","title":"康诺亚-B(02162)：王闽川辞任非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2665646113","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665646113?lang=zh_cn&edition=full","pubTime":"2026-09-06 18:42","pubTimestamp":1788691337,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康诺亚-B(02162)发布公告，王闽川博士已递交辞呈，辞去公司非执行董事职务，自2026年9月4日起生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492491.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1587","BK1161","BK1574","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665364619","title":"康诺亚-B(02162.HK)：王闽川辞任非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2665364619","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665364619?lang=zh_cn&edition=full","pubTime":"2026-09-06 18:42","pubTimestamp":1788691337,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1161","02162","BK1583","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107689505","title":"康诺亚-B（02162）公布董事会及三大专门委员会组成人员名单","url":"https://stock-news.laohu8.com/highlight/detail?id=1107689505","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107689505?lang=zh_cn&edition=full","pubTime":"2026-09-06 18:36","pubTimestamp":1788690990,"startTime":"0","endTime":"0","summary":"2026年9月6日，康诺亚生物医药科技有限公司在港交所发布公告，披露公司董事会最新成员组成及其在审核委员会、薪酬委员会、提名委员会中的职能分工。根据公告，具体安排如下：。公司在公告结尾处确认，本次披露内容自2026年9月6日起生效。公司并未在本公告中披露任何财务数据或经营指标。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126459483","title":"康诺亚-B（02162.HK）：王闽川博士将于2026年9月4日辞任非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=1126459483","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126459483?lang=zh_cn&edition=full","pubTime":"2026-09-06 18:31","pubTimestamp":1788690663,"startTime":"0","endTime":"0","summary":"康诺亚生物医药科技有限公司9月6日公告称，董事会收到王闽川博士的辞呈。王博士将于2026年9月4日起正式辞去公司非执行董事职务。同时，王博士确认，关于其离任并无其他需提请公司股东或香港联合交易所有限公司关注的事项。\\n\\n董事会对王博士在任期内作出的贡献表示感谢，并将于其离任生效后履行相关董事会职责安排。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664238859","title":"【券商聚焦】交银国际：医药行业收入稳健增长 多重利好推动盈利表现显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2664238859","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664238859?lang=zh_cn&edition=full","pubTime":"2026-09-04 09:00","pubTimestamp":1788483634,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，1H26港股/A股医药行业整体收入增长4.7%/3.2%。创新药产业链增速领跑行业，服务板块复苏：1）港股/A股CXO收入整体增长29.2%/25.3%，（扣非）净利润增长23.4%/67.6%，在各子板块中增速最快，行业整体景气度和订单需求处于高位。2）核心成药板块收入增长17.8%/3.4%、利润增长62.7%/35.0%。其中生物药增速远超化药，在板块收入中的占比也进一步提升。3）医院、器械、诊断、疫苗等板块业绩有复苏趋势。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990646","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996","09996","IE00B0JY6N72.USD","03759","06821","LU1242518857.USD","00013","01093","06160","01951","LU2543165471.USD","LU0039217434.USD","LU0348783233.USD","02596","06078","01548","01530","LU0856984785.SGD","LU1880383366.USD","01952","BK1161","BK1589","03329","02268","09966","06990","LU1152091168.USD","01801","BK1209","LU0588546209.SGD","02273","LU0327786744.USD","02269","HK0000306685.HKD","01276","BK1515","IE00B5MMRT66.SGD","01177","02162","HK0000320264.USD","LU0315179316.USD","SG9999004220.SGD","IE00B543WZ88.USD","KURE","LU0307460666.USD","09926","KCE","02096","LU1251922891.USD","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664592821","title":"港股异动 | 康诺亚-B(02162.HK)涨超3% 公司国际化战略迎重要里程碑 与Aeira签署独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2664592821","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664592821?lang=zh_cn&edition=full","pubTime":"2026-09-03 14:08","pubTimestamp":1788415700,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1161","02162","BK1587","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112572646","title":"康诺亚-B与Aeira签订司普奇拜单抗东南亚及中亚18国独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1112572646","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112572646?lang=zh_cn&edition=full","pubTime":"2026-09-02 21:05","pubTimestamp":1788354349,"startTime":"0","endTime":"0","summary":"2026年9月2日，康诺亚生物医药科技有限公司公告称，公司已与跨国医药公司Aeira Pte. Ltd.签署独家许可协议，涉及自主研发的靶向IL-4Rα单克隆抗体司普奇拜单抗注射液在东南亚、中亚及港澳地区共18个国家和地区的上市注册与商业化。具体金额与比例未在公告中披露。康诺亚将持续负责该产品的生产及供应。康诺亚同时提醒投资者，司普奇拜单抗在上述区域的开发、上市及商业化存在不确定性，投资者买卖公司股票时应审慎行事。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664546816","title":"东方证券股份有限公司(DFZQ)减持康诺亚-B(02162.HK)4.8万股 每股作价78.401港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664546816","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664546816?lang=zh_cn&edition=full","pubTime":"2026-09-02 19:19","pubTimestamp":1788347999,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1564","03958","BK1583","BK1574","02162","BK1587","BK1147"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113968167","title":"康诺亚-B公布2026年8月股份变动月报表，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1113968167","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113968167?lang=zh_cn&edition=full","pubTime":"2026-09-02 16:58","pubTimestamp":1788339492,"startTime":"0","endTime":"0","summary":"康诺亚生物医药科技有限公司于2026年9月2日发布2026年8月股份变动月报表，报告期截至2026年8月31日。公告显示，公司本月底法定注册股本为500,000,000股普通股，每股面值为USD 0.0001，合计USD 50,000，与上月底保持一致。在已发行股份方面，截至8月末，康诺亚-B普通股已发行股份数量为298,735,566股，月内无增发、购回或注销活动，库藏股数量保持0股。此外，报告期内并无涉及股份期权计划、可换股票据及其他关联协议的变动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0839},{"period":"1month","weight":-0.0682},{"period":"3month","weight":0.0339},{"period":"6month","weight":0.0918},{"period":"1year","weight":0.0405},{"period":"ytd","weight":0.3686}],"compareEarnings":[{"period":"1week","weight":-0.016},{"period":"1month","weight":-0.0368},{"period":"3month","weight":0.077},{"period":"6month","weight":-0.0258},{"period":"1year","weight":-0.0569},{"period":"ytd","weight":-0.0385}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康诺亚生物医药科技有限公司是一家生物科技公司，专注于自主发现及开发自体免疫及肿瘤治疗领域的创新生物疗法的公司。该公司还专注于医药产品的研究和开发。该公司的主要产品有CM310、CM326、CM313和CM383，可治疗各种成人、青少年及儿童I型免疫性疾病，例如中重度特应性皮炎、中重度哮喘、慢性鼻賨炎伴鼻息肉、过敏性鼻炎，亦可能可以治疗慢性阻塞性肺疾病。该公司还建立了涵盖生物药开发的关键功能的全面一体化平台。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.062159},{"month":2,"riseRate":0.6,"avgChangeRate":0.057033},{"month":3,"riseRate":0.4,"avgChangeRate":0.01927},{"month":4,"riseRate":1,"avgChangeRate":0.079263},{"month":5,"riseRate":0.2,"avgChangeRate":-0.114444},{"month":6,"riseRate":1,"avgChangeRate":0.128513},{"month":7,"riseRate":0.6,"avgChangeRate":0.112367},{"month":8,"riseRate":0.666667,"avgChangeRate":0.036143},{"month":9,"riseRate":0.666667,"avgChangeRate":0.031561},{"month":10,"riseRate":0.4,"avgChangeRate":0.003137},{"month":11,"riseRate":0.6,"avgChangeRate":0.04569},{"month":12,"riseRate":0.2,"avgChangeRate":-0.144855}],"exchange":"SEHK","name":"康诺亚-B","nameEN":"KEYMED BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康诺亚-B(02162)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康诺亚-B(02162)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康诺亚-B,02162,康诺亚-B股票,康诺亚-B股票老虎,康诺亚-B股票老虎国际,康诺亚-B行情,康诺亚-B股票行情,康诺亚-B股价,康诺亚-B股市,康诺亚-B股票价格,康诺亚-B股票交易,康诺亚-B股票购买,康诺亚-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康诺亚-B(02162)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康诺亚-B(02162)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}